Skip to main content
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1993 Jul;30(7):562–566. doi: 10.1136/jmg.30.7.562

Genetic risk: women's understanding of carrier risks in Duchenne muscular dystrophy.

E P Parsons 1, A J Clarke 1
PMCID: PMC1016455  PMID: 8411028

Abstract

This paper reports a study of 48 women (16 mothers and 32 daughters representing 28 families) who had lived with Duchenne muscular dystrophy (DMD) in their family. It looks at the way the women talked about their carrier risks during the course of an unstructured interview. It points to a significant difference between lay and health professionals' perspectives, in particular the thresholds they used to distinguish between high and low risk. A number of women, when quoting their risk in a mathematical form, confused their reproductive risks with their carrier risk, another indication of differential perceptions between the women and health professionals. There was evidence that several of the women did not retain their risk in a mathematical form but had translated it into a descriptive category which resolved their risk into greater certainty.

Full text

PDF
566

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cobb E., Holloway S., Elton R., Raeburn J. A. What do young people think about screening for cystic fibrosis? J Med Genet. 1991 May;28(5):322–324. doi: 10.1136/jmg.28.5.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Kerem B., Rommens J. M., Buchanan J. A., Markiewicz D., Cox T. K., Chakravarti A., Buchwald M., Tsui L. C. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989 Sep 8;245(4922):1073–1080. doi: 10.1126/science.2570460. [DOI] [PubMed] [Google Scholar]
  3. Margolin C. R. Attitudes toward control and elimination of genetic defects. Soc Biol. 1978 Spring;25(1):33–37. doi: 10.1080/19485565.1978.9988316. [DOI] [PubMed] [Google Scholar]
  4. Modell B., Petrou M., Ward R. H., Fairweather D. V., Rodeck C., Varnavides L. A., White J. M. Effect of fetal diagnostic testing on birth-rate of thalassaemia major in Britain. Lancet. 1984 Dec 15;2(8416):1383–1386. doi: 10.1016/s0140-6736(84)92070-1. [DOI] [PubMed] [Google Scholar]
  5. Riordan J. R., Rommens J. M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J. L. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066–1073. doi: 10.1126/science.2475911. [DOI] [PubMed] [Google Scholar]
  6. Ten Kate L. P., Tijmstra T. Carrier screening for cystic fibrosis. Lancet. 1989 Oct 21;2(8669):973–974. doi: 10.1016/s0140-6736(89)90975-6. [DOI] [PubMed] [Google Scholar]
  7. Wilfond B. S., Fost N. The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA. 1990 May 23;263(20):2777–2783. [PubMed] [Google Scholar]
  8. Williamson R., Allison M. E., Bentley T. J., Lim S. M., Watson E., Chapple J., Adam S., Boulton M. Community attitudes to cystic fibrosis carrier testing in England: a pilot study. Prenat Diagn. 1989 Oct;9(10):727–734. doi: 10.1002/pd.1970091008. [DOI] [PubMed] [Google Scholar]
  9. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet. 1990 Jul 7;336(8706):1–6. [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES